Savoy Pharmaceuticals works with a quality set of partners and collaborators to ensure the best expertise and technologies are applied to our discovery and development efforts.
Savoy Pharmaceuticals has conducted exhaustive research and development to validate TK1 as a marker for cancer therapy. To assess Oncoprev's potential as a cancer treatment, we performed experiments with our murine antibody to determine if Oncoprev would differentially bind to the surface of cancer cells but not normal cells. We used several techniques; immunofluorescent assay (IFA), Immunohistochemistry (IHC), flow cytometry, ELISA, complement mediated lysis (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and murine xenografts. We have also developed 6 fully human candidate antibodies with exceptional binding specificity, which we plan to take into human clinical trials.
We outsourced much of our research and the contact information for some of the laboratories with whom we have worked is listed below.
Cybrdi is the pioneer and primary provider of tissue array products. Cybrdi has
established a comprehensive and integrated system to collect various normal and diseased
tissues focusing on the fields of oncology. Cybrdi manufactures in consistent high quality
various tissue arrays in different formats. Cybrdi assists researchers to identify, verify and
validate molecules of diagnostic and therapeutic importance. Cybrdi provides services as well,
including histo-pathology services, immunohistochemistry, ffpe block or fresh frozen tissue
section/special staining, antibody EC50/IC50 determination, CDC/ADCC assays, custom TMA
development, primary cell establishment and techniques and methods in cancer used in drug
Piedmont Research Center ("Piedmont") is the premier contract research service organization focused on developing and validating potential anti-cancer agents. Piedmont's highly educated staff of professionals includes some of the most respected oncologists and researchers in the field. The company provides a full spectrum of in vivo and in vitro research services and products at its 28,000 square foot AAALAC accredited facility, located in the heart of Research Triangle Park, North Carolina. AALAS certified staff ensures the conduct of Savoy high quality in vivo studies that are the hallmark of Piedmont. Piedmont Research Center was founded in 1997. In 2002, Piedmont became the wholly owned subsidiary of PPD. After five years of substantial growth, it was acquired by Charles River Laboratories International, Inc. in May, 2009.
LifeSpan BioSciences is a global provider of catalog antibodies, custom antibodies, tissue microarrays, and immunohistochemistry (IHC) services.
Monoclonal antibody Isotype switching and TK1 surface quantification
The mission of Dana-Farber Cancer Institute, which, recently raised $1.18 billion, is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. As an affiliate of Harvard Medical School and a Comprehensive Cancer Center designated by the National Cancer Institute, the Institute also provides training for new generations of physicians and scientists, designs programs that promote public health particularly among high-risk and underserved populations, and disseminates innovative patient therapies and scientific discoveries to our target community across the United States and throughout the world.
Dana-Farber Cancer Institute's ultimate goal is the eradication of cancer, AIDS, and related diseases and the fear that they engender.
Thymidine Kinase 1 Surface Quantification and Conjugation of Antibody to Toxin
Michael Rosenblum - Professor of Medicine
Head, Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center
Dr. Rosenblum's primary interest is in the pharmacology of biological agents, particularly proteins, which are capable of targeting selected cells and developing tumor cell-targeted cytotoxic agents. Additionally, he is interested in tumor cell-signaling events and employing signaling strategies to achieve therapeutic goals.
Commonwealth Biotechnologies, Inc., was founded in 1992 to provide sophisticated
research and development support services on a fee-for-service basis to the global
biotechnology and pharmaceutical industry. Since 2004, CBI has pursued a strategy of
acquiring or merging with complementary companies that extend its drug discovery capabilities
and earnings potential. The anticipated protein staining pattern for TK1 was observed, and is in
good agreement with that provided by Abnova. The antibody clearly recognizes multiple forms
of the protein, including TK1 dimer, and lower molecular weight forms in the protein preparation.
Asim Dasgupta is a virologist and molecular biologist who has served on the UCLA School of Medicine faculty since he joined the Department of Microbiology, Immunology and Molecular Genetics in 1981.
He became a full professor in 1989 and has served as Graduate advisor for the department from 1984 to 1995.
He also served as the Vice-Chairman of the department from 1992-1995.
Dr. Dasgupta earned his B.S. in Chemistry and M.S. Biochemistry from Calcutta University, India, followed by a Ph.D. degree in Chemistry/Biochemistry from the University of Nebraska-Lincoln.
He was a postdoctoral fellow at the Massachusetts Institutes of Technology, where he worked on RNA virus replication in the laboratory of Nobel Laureate Dr. David Baltimore.
Dr. Dasgupta received the prestigious American Cancer Society Faculty Research award as well as the NIH Career Development Award.
His laboratory research centers on RNA virus replication as well as transcriptional and translational control in cells infected with mammalian RNA viruses such as poliovirus, rhinovirus and hepatitis C virus (HCV).
In 1994, Dr. Dasgupta's laboratory discovered a natural antiviral molecule from the yeast S. cerevisiae, which was shown to specifically block internal ribosome entry site (IRES)-mediated translation of viral RNAs.
Currently a major focus of his laboratory has been to design molecules that specifically interfere with HCV genome translation and replication.